日本語 
Recruitment for this clinical study is now complete, and we are no longer accepting new participants. Thank you for your interest
Recruitment for this clinical study is now complete, and we are no longer accepting new participants. Thank you for your interest
Hoyler TF, Strasser DS, Berkani O, et al. LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis. Lupus Sci Med. 2023;10.